Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Mesa Laboratories (MLAB) Shares Outstanding (Weighted Average) (2017 - 2023)

Historic Shares Outstanding (Weighted Average) for Mesa Laboratories (MLAB) over the last 11 years, with Q4 2023 value amounting to $5.4 million.

  • Mesa Laboratories' Shares Outstanding (Weighted Average) rose 101.14% to $5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.4 million, marking a year-over-year increase of 101.14%. This contributed to the annual value of $3.5 million for FY2015, which is 220.61% up from last year.
  • Per Mesa Laboratories' latest filing, its Shares Outstanding (Weighted Average) stood at $5.4 million for Q4 2023, which was up 101.14% from $5.4 million recorded in Q3 2023.
  • In the past 5 years, Mesa Laboratories' Shares Outstanding (Weighted Average) registered a high of $5.4 million during Q4 2023, and its lowest value of $5.2 million during Q3 2021.
  • In the last 3 years, Mesa Laboratories' Shares Outstanding (Weighted Average) had a median value of $5.3 million in 2022 and averaged $5.3 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 214.93% in 2022, then skyrocketed by 101.14% in 2023.
  • Mesa Laboratories' Shares Outstanding (Weighted Average) (Quarter) stood at $5.2 million in 2021, then rose by 2.03% to $5.3 million in 2022, then increased by 1.01% to $5.4 million in 2023.
  • Its last three reported values are $5.4 million in Q4 2023, $5.4 million for Q3 2023, and $5.3 million during Q4 2022.